

## **AMENDMENT**

## In the Claims:

## Please replace original claims 1-13 with the following claims:

1. A process for the preparation of a dipeptide of formula 1 comprising

Al

coupling N-protected L-leucine to L-tert.-leucine-N-methylamide in the presence of an activating agent, wherein G is a protective group that is a formyl group.

- 2. The process according to claim 1 in which the L-tert.-leucine-N-methylamide has an enantiomeric excess greater than 98%
- 3. The process according to claim 1 in which the N-formyl-L-leucine has an enantiomeric excess greater than 98%.
- 4. The process according to claim 1 further comprising subjecting the N-formyl-L-leucyl-L-tert.-leucine-N-methylamide obtained to one or more crystallizations.
- 5. The process according to claim 1 further comprising deformylating the dipeptide obtained.
- 6. The process according to claim 5 further comprising subjecting the L-leucyl-L-tert.-leucine-N-methylamide obtained to one or more crystallizations.

To a distribution and the same and the same

- 7. The process according to claim 5 further comprising coupling the L-leucyl-Ltert.-leucine-N-methylamide to a substituted or nonsubstituted  $\alpha$ -mercaptocarboxylic acid to form the corresponding N- $\alpha$ -optionally substituted mercaptocarboxyl-L-leucyl-L-tert.-leucine-Nmethylamide.
  - 8. A compound which is N-formyl-L-leucyl-L-tert.-leucine-N-methylamide.
- 9. A composition comprising the N-formyl-L-leucyl-L-*tert*.-leucine-N-methylamide defined in claim 8 wherein an enantiomeric excess is present of the N-terminal amino acid in the dipeptide of more than 80%.
- 10. The composition according to claim 9 wherein the enantiomeric excess of the N-terminal amino acid in the dipeptide is more than 98%.
- 11. The composition according to claim 9 wherein a diastereomeric excess is present of more than 80%.
- 12. The composition according to claim 11 with a diastereomeric excess of more than 98%.
- 13. A pharmaceutical composition comprising N-formyl-L-leucyl-L-tert.-leucine-N-methylamide according to claim 8 and a pharmaceutically acceptable excipient.